Lp-PLA2: what your result means.

An enzyme in arterial plaque that signals active vascular inflammation. Lp-PLA2 is measured by blood test as part of the Cardiovascular panel in the HodieLabs Health Blueprint.

Why Lp-PLA2 matters

Interpret with ApoB, hs-CRP and overall risk profile. Interpret using the reporting lab’s reference interval and clinical context; trend over time is often more informative than a single value.

Associated risks when out of range: Vascular inflammation. Plaque activity.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets Lp-PLA2, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• Lp-PLA2 Studies Collaboration (The Lancet 2010): across 32 prospective studies (~79,000 participants), Lp-PLA2 was associated with coronary disease and vascular mortality at a strength comparable to non-HDL cholesterol or blood pressure, a vascular-specific inflammation signal.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets Lp-PLA2 against published clinical authority standards, never arbitrary "optimal" ranges. Measured in U/L or ng/mL (lab dependent):

Clinical interpretation

• Interpret with ApoB, hs-CRP and overall risk profile.
• Interpret using the reporting lab’s reference interval and clinical context; trend over time is often more informative than a single value.

What improves it: the evidence-based levers

• ApoB optimisation
• Anti-inflammatory lifestyle
• Specialist discussion if elevated

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How Lp-PLA2 testing works at HodieLabs

Lp-PLA2 is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–1544.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.